Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Halozyme Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 35.9%. For fiscal 2025 it was 33.6%, against 54.3% the year before. The highest annual figure on record is 62.2% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.6% | −20.7 |
| FY2024 | Dec 31, 2024 | 54.3% | +13.6 |
| FY2023 | Dec 31, 2023 | 40.7% | +0.2 |
| FY2022 | Dec 31, 2022 | 40.5% | −21.7 |
| FY2021 | Dec 31, 2021 | 62.2% | +8.3 |
| FY2020 | Dec 31, 2020 | 53.9% | +88.4 |
| FY2019 | Dec 31, 2019 | -34.5% | +11.2 |
| FY2018 | Dec 31, 2018 | -45.7% | −71.2 |
| FY2017 | Dec 31, 2017 | 25.6% | +82.3 |
| FY2016 | Dec 31, 2016 | -56.7% | −36.4 |
| FY2015 | Dec 31, 2015 | -20.3% | +63.3 |
| FY2014 | Dec 31, 2014 | -83.7% | +63.1 |
| FY2013 | Dec 31, 2013 | -146.8% | −20.1 |
| FY2012 | Dec 31, 2012 | -126.7% | −91.3 |
| FY2011 | Dec 31, 2011 | -35.4% | +362.9 |
| FY2010 | Dec 31, 2010 | -398.2% | +29.4 |
| FY2009 | Dec 31, 2009 | -427.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 59.8% | −2.3 |
| Q1 FY2026 | Mar 31, 2026 | 49.0% | −4.5 |
| Q4 FY2025 | Dec 31, 2025 | -20.6% | −79.5 |
| Q3 FY2025 | Sep 30, 2025 | 61.5% | +5.3 |
| Q2 FY2025 | Jun 30, 2025 | 62.2% | +11.5 |
| Q1 FY2025 | Mar 31, 2025 | 53.4% | +4.7 |
| Q4 FY2024 | Dec 31, 2024 | 58.9% | +15.0 |
| Q3 FY2024 | Sep 30, 2024 | 56.3% | +15.4 |
| Q2 FY2024 | Jun 30, 2024 | 50.7% | +7.9 |
| Q1 FY2024 | Mar 31, 2024 | 48.8% | +15.6 |
| Q4 FY2023 | Dec 31, 2023 | 43.9% | +2.9 |
| Q3 FY2023 | Sep 30, 2023 | 40.9% | +1.0 |
| Q2 FY2023 | Jun 30, 2023 | 42.7% | +20.4 |
| Q1 FY2023 | Mar 31, 2023 | 33.2% | −31.3 |
| Q4 FY2022 | Dec 31, 2022 | 41.1% | −14.4 |
| Q3 FY2022 | Sep 30, 2022 | 39.9% | −25.4 |
| Q2 FY2022 | Jun 30, 2022 | 22.4% | −45.8 |
| Q1 FY2022 | Mar 31, 2022 | 64.5% | +7.5 |
| Q4 FY2021 | Dec 31, 2021 | 55.4% | −8.4 |
| Q3 FY2021 | Sep 30, 2021 | 65.3% | +3.6 |
| Q2 FY2021 | Jun 30, 2021 | 68.2% | +14.7 |
| Q1 FY2021 | Mar 31, 2021 | 57.0% | +69.7 |
| Q4 FY2020 | Dec 31, 2020 | 63.8% | +123.5 |
| Q3 FY2020 | Sep 30, 2020 | 61.7% | +114.8 |
| Q2 FY2020 | Jun 30, 2020 | 53.5% | +89.2 |
| Q1 FY2020 | Mar 31, 2020 | -12.7% | −17.9 |
| Q4 FY2019 | Dec 31, 2019 | -59.7% | −59.6 |
| Q3 FY2019 | Sep 30, 2019 | -53.1% | +46.6 |
| Q2 FY2019 | Jun 30, 2019 | -35.7% | +21.3 |
| Q1 FY2019 | Mar 31, 2019 | 5.2% | +82.0 |
| Q4 FY2018 | Dec 31, 2018 | -0.1% | −66.5 |
| Q3 FY2018 | Sep 30, 2018 | -99.7% | −112.4 |
| Q2 FY2018 | Jun 30, 2018 | -57.0% | +18.5 |
| Q1 FY2018 | Mar 31, 2018 | -76.8% | +16.3 |
| Q4 FY2017 | Dec 31, 2017 | 66.4% | +124.3 |
| Q3 FY2017 | Sep 30, 2017 | 12.7% | +84.1 |
| Q2 FY2017 | Jun 30, 2017 | -75.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -93.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -57.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -71.4% | – |
See a number that looks wrong?